Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 440

1.

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.

Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2012 Sep 14;11:107.

2.

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2011 Dec 1;10:109. doi: 10.1186/1475-2840-10-109.

3.

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.

de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K.

Int J Clin Pharm. 2016 Feb;38(1):144-51. doi: 10.1007/s11096-015-0219-8. Epub 2015 Nov 23.

4.

Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.

Suzuki D, Toyoda M, Kimura M, Miyauchi M, Yamamoto N, Sato H, Tanaka E, Kuriyama Y, Miyatake H, Abe M, Umezono T, Fukagawa M.

Intern Med. 2013;52(10):1029-34. Epub 2013 May 15.

5.
6.

Long-term effectiveness and safety of liraglutide in clinical practice.

Ponzani P.

Minerva Endocrinol. 2013 Mar;38(1):103-12.

PMID:
23435446
7.
8.

The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.

Lane W, Weinrib S, Rappaport J, Hale C.

Diabetes Obes Metab. 2014 Sep;16(9):827-32. doi: 10.1111/dom.12286. Epub 2014 Mar 25.

PMID:
24589127
9.

Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.

Santilli F, Simeone PG, Guagnano MT, Leo M, Maccarone MT, Di Castelnuovo A, Sborgia C, Bonadonna RC, Angelucci E, Federico V, Cianfarani S, Manzoli L, Davì G, Tartaro A, Consoli A.

Diabetes Care. 2017 Nov;40(11):1556-1564. doi: 10.2337/dc17-0589. Epub 2017 Sep 14.

PMID:
28912305
10.

Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.

Feng P, Yu DM, Chen LM, Chang BC, Ji QD, Li SY, Zhu M, Ding SH, Zhang BZ, Wang SL, Li HT, Lin JN, Wang MJ, Guo JC, Liu J, Liu ZD, Wu ST, Yang JH.

Acta Pharmacol Sin. 2015 Feb;36(2):200-8. doi: 10.1038/aps.2014.136. Epub 2015 Jan 26.

11.

Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.

Kuhadiya ND, Malik R, Bellini NJ, Patterson JL, Traina A, Makdissi A, Dandona P.

Endocr Pract. 2013 Nov-Dec;19(6):963-7. doi: 10.4158/EP13065.OR.

PMID:
23807520
12.

The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.

Lane W, Weinrib S, Rappaport J.

Diabetes Technol Ther. 2011 May;13(5):592-5. doi: 10.1089/dia.2010.0221. Epub 2011 Mar 15.

PMID:
21406014
13.

Liraglutide effective in the severely insulin-resistant patient with type 2 diabetes requiring U-500 insulin: a case report.

Pantalone KM, Faiman C.

Diabetes Technol Ther. 2013 Apr;15(4):342-3. doi: 10.1089/dia.2012.0328. Epub 2013 Feb 4.

PMID:
23379638
14.

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.

D'Alessio D, Häring HU, Charbonnel B, de Pablos-Velasco P, Candelas C, Dain MP, Vincent M, Pilorget V, Yki-Järvinen H; EAGLE Investigators.

Diabetes Obes Metab. 2015 Feb;17(2):170-8. doi: 10.1111/dom.12406. Epub 2014 Dec 7.

PMID:
25359159
16.

Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.

Li CJ, Yu Q, Yu P, Zhang QM, Ding M, Liu XJ, Yu DM.

Exp Clin Endocrinol Diabetes. 2014 Sep;122(8):469-76. doi: 10.1055/s-0034-1374586. Epub 2014 May 16.

PMID:
24838155
17.

Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.

Díaz-Soto G, de Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E.

Diabetes Res Clin Pract. 2014 Apr;104(1):92-6. doi: 10.1016/j.diabres.2014.01.019. Epub 2014 Jan 25.

PMID:
24530118
18.

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.

van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH.

Int J Obes (Lond). 2014 Jun;38(6):784-93. doi: 10.1038/ijo.2013.162. Epub 2013 Sep 3.

19.

Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.

Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, Avogaro A.

Acta Diabetol. 2013 Dec;50(6):943-9. doi: 10.1007/s00592-013-0489-3. Epub 2013 Jun 11.

PMID:
23754673
20.

A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice.

van Velsen EF, Lamers J, Blok V, van Leendert RJ, Kiewiet-Kemper RM.

Neth J Med. 2014 Dec;72(10):523-7.

Supplemental Content

Support Center